Akeso, Inc. Launches Promising Phase III Study for Lung Cancer Treatment

Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.

Akeso, Inc. has announced a new clinical study titled ‘A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112 (PD-1/VEGF Bispecific Antibody) Versus Placebo as Consolidation Treatment for Patients With Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy.’ The study aims to evaluate the efficacy and safety of AK112 as a consolidation treatment for patients with small-cell lung cancer who have not progressed after chemoradiation therapy, highlighting its potential significance in improving patient outcomes.

The intervention being tested is AK112, a PD-1/VEGF bispecific antibody, administered intravenously every three weeks. This drug is designed to enhance treatment efficacy by targeting specific cancer pathways.

The study is designed as a randomized, double-blind, phase III trial with a parallel assignment model. It employs triple masking, meaning that participants, care providers, and investigators are unaware of the treatment allocations, ensuring unbiased results. The primary purpose of the study is treatment-focused.

The study is not yet recruiting, with the first submission date on May 25, 2025, and the last update on June 5, 2025. These dates are crucial as they mark the beginning of the study’s timeline and its progression towards completion.

For investors, this study represents a significant development for Akeso, Inc., potentially influencing its stock performance positively if the results demonstrate AK112’s efficacy. The study’s outcome could also impact the competitive landscape in the oncology sector, where advancements in treatment options are highly valued.

The study is ongoing, with further details available on the ClinicalTrials portal.